Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Jun;21(6):e14333.
doi: 10.1002/alz.14333. Epub 2024 Dec 23.

Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care

Affiliations
Practice Guideline

Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care

Alireza Atri et al. Alzheimers Dement. 2025 Jun.

Abstract

US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence-based guideline was developed to empower all-including primary care-clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. Through a modified-Delphi approach and guideline-development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient-centered evaluation process. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high-quality, evidence-supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive-behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health-care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence-based guideline was developed to empower all-including primary care-clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high-quality, evidence-supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive-behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health-care systems provide adequate resources, outcomes should improve in most patients in most practice settings.

Keywords: Alzheimer's disease; Lewy body dementia; cerebrospinal fluid; dementia; diagnosis; frontotemporal dementia; magnetic resonance imaging; mild cognitive impairment; molecular biomarkers; positron emission tomography; vascular cognitive impairment.

PubMed Disclaimer

Conflict of interest statement

Bradford C. Dickerson: consulting for Acadia, Alector, Arkuda, Biogen, Eisai, Med Learning Group, Quanterix; on DSMB for Lilly, Merck; royalties from Cambridge University Press, Elsevier, Oxford University Press, Up To Date. Alireza Atri: consulting for Acadia, AriBio, AZ Therapies, Biogen, Eisai, JOMDD, Lundbeck, Life Molecular Imaging, Merck, ONO, Prothena, Roche/Genentech, Novo Nordisk, Qynapse, Vaxxinity; royalties from Oxford University Press. Carolyn Clevenger: none. Jason Karlawish: on a DSMB for Linus Health. David Knopman: on a DSMB for DIAN TU. Pei‐Jung Lin: consulting for Lilly. Mary Norman: none. Chiadi Onyike: consulting for Acadia Pharmaceuticals, Reata Pharmaceuticals, Otsuka Pharmaceutical, Eisai Pharmaceutical, Lykos Therapeutics, Zevra Therapeutics. Mary Sano: consulting for Eisai, NovoNordisk, Otsuka Lundbeck. Susan Scanland: employee of Dementia Connection, LLC; consulting for Axsome, BioXcel, Eisai, Genentech, Lundbeck, Otsuka. Maria Carrillo: employee of Alzheimer's Association. Author disclosures are available in the supporting information.

Figures

FIGURE 1
FIGURE 1
For patients who may be exhibiting symptoms and/or signs of cognitive impairment due to AD or ADRD, the three steps of the diagnostic formulation may be accomplished by following a process of seven core elements. AD, Alzheimer's disease; ADRD, Alzheimer's disease and related dementias, Dx, diagnosis; Hx, history.
FIGURE 2
FIGURE 2
In a primary care setting, this diagram shows the implementation of the seven core elements of the diagnostic evaluation process, illustrating how each clinical practice recommendation fits into the typical workflow, using the first tier of assessments and diagnostic tests. Ultimately, the goal is to evaluate a person with cognitive and/or behavioral symptoms to determine whether they have cognitive impairment and if so its impact on daily function (cognitive functional status), the cognitive–behavioral syndrome, and the likely etiology (‐ies) of the impairment. This diagnostic formulation should then be disclosed clearly and compassionately, and a treatment plan can then be initiated. CBC, complete blood count; CRP, C‐reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; MRI, magnetic resonance imaging; TSH, thyroid‐stimulating hormone.
FIGURE 3
FIGURE 3
In a specialty care setting (usually general neurology, geriatric psychiatry, or geriatrics), this diagram briefly illustrates how each primary care clinical practice recommendation fits into the typical workflow (see Figure 2 for details). Additional detail is provided on how higher tier assessments and diagnostic tests fit into the specialty care workflow. In some specialty care settings, the assessments and tests illustrated in Figure 4 are performed to arrive at the three‐step diagnostic formulation. This diagnostic formulation should then be disclosed clearly and compassionately, and a treatment plan can then be initiated.
FIGURE 4
FIGURE 4
In a dementia subspecialty care setting (usually behavioral or geriatric neurology, geriatric or neuropsychiatry, or geriatrics), this diagram briefly illustrates how each primary care or specialty clinical practice recommendation fits into the typical workflow (see Figures 2 and 3 for details). Additional detail is provided on how higher tier assessments and diagnostic tests fit into the subspecialty care workflow to arrive at the three‐step diagnostic formulation. This diagnostic formulation should then be disclosed clearly and compassionately, and a treatment plan can then be initiated. CBC, complete blood count; CRP, C‐reactive protein; CT, computed tomography; DDx, differential diagnosis; Dx, diagnosis; ESR, erythrocyte sedimentation rate; MRI, magnetic resonance imaging; TSH, thyroid‐stimulating hormone.

References

    1. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19:1598‐1695. - PubMed
    1. 2020 Alzheimer's disease facts and figures. Alzheimers Dementia. 2020;16:391‐460. - PubMed
    1. El‐Hayek YH, Wiley RE, Khoury CP, et al. Tip of the Iceberg: assessing the Global Socioeconomic Costs of Alzheimer's disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis. 2019;70:323‐341. - PMC - PubMed
    1. 2018 Alzheimer's disease facts and figures. Alzheimers Dementia. 2018;14:367‐429.
    1. Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu Y‐T, Prina M. World Alzheimer Report 2015 ‐ The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer's Disease International; 2015:82.

Publication types